New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
09:15 EDTIN, CLDX, NXY, MCD, HON, ZGNX, CEOOn The Fly: Pre-market Movers
HIGHER: Intermec (IN), up 22.8% after agreeing to be acquired by Honeywell (HON) for $10.00 per share in cash... Nexen (NXY), up 14.6% after Canada approves acquisition by CNOOC (CEO)... Celldex (CLDX), up 8.5% after reporting results from phase 2b trial of breast cancer drug... McDonald's (MCD), up 1.9% after November SSS beat expectations... LOWER: Zogenix (ZGNX), down 39% after FDA panel votes against approval of Zohydro ER.
News For IN;HON;NXY;CEO;MCD;CLDX;ZGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 27, 2015
08:44 EDTZGNXZogenix announces new efficacy data from study of low-dose fenfluramine
Zogenix announced new data demonstrating sustained efficacy and tolerability for patients treated with low-dose fenfluramine as an adjunctive therapy for Dravet syndrome. The data was authored by world-renown experts in the field of Dravet syndrome, Berten Ceulemans, M.D., Ph.D. and Lieven Lagae, M.D., Ph.D., from the Universities of Antwerp and Leuven in Belgium, and was presented at the European Paediatric Neurology Society meeting taking place this week in Vienna, Austria. Zogenix intends to initiate Phase 3 clinical studies for ZX008, the company's investigational proprietary pediatric formulation of low-dose fenfluramine, during the second half of 2015. ZX008 is designated as an orphan drug in both the U.S. and Europe for the treatment of Dravet syndrome. The results presented are from the latest 5-year follow-up period in a group of Dravet syndrome patients being treated with low-dose fenfluramine. This analysis, which includes ten patients from the original study group and two patients who began treatment in 2011, demonstrated that during any given year of the follow-up period, at least 80% of patients achieved a greater than or equal to 75% reduction in the frequency of seizures. In addition, three patients were seizure-free for all 5 years and five patients were seizure-free for 2 to 4 years. The use of low-dose fenfluramine in this group of patients was shown to be generally well tolerated, with the most common adverse events being transient loss of appetite and fatigue/somnolence. No clinically meaningful cardiac adverse events were noted. No patient discontinued treatment due to adverse events. In addition, a recently published translational research study to elucidate fenfluramine's mechanism of action in Dravet syndrome demonstrated the ability of fenfluramine to significantly reduce locomotion and eliminate epileptiform EEG activity in a gene knockdown zebrafish model of Dravet syndrome. These data support the clinical results obtained in the Belgium cohort of patients.
08:04 EDTCEOChina oil demand increase to boost oil equities, says Bernstein
Subscribe for More Information
05:34 EDTCEOCNOOC makes mid-sized discovery Linhua 20-2 in South China Sea
CNOOC announced that the company made a mid-sized discovery Liuhua 20-2 in the Eastern South China Sea. The Liuhua 20-2 structure is located in Northern Slope Belt of Baiyun Sag in the Pearl River Mouth Basin of the South China Sea with an average water depth of about 390 meters. The discovery well LH20-2-1 was drilled and completed at a depth of about 2,970 meters and encountered oil pay zones with a total thickness of 35.2 meters. The oil production of the well tested around 8,000 barrels per day and the crude oil density is approximately 0.75. The exploration of Liuhua 20-2 has further proved the huge exploration potential of Baiyun Sag in the Pearl River Mouth Basin, and Baiyun Sag is expected to become the new reserves growth area of deepwater exploration of crude oil in South China Sea.
May 26, 2015
09:58 EDTCEOOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: L Brands (LB) upgraded to Conviction Buy from Buy at Goldman... Dollar General (DG) upgraded to Conviction Buy from Buy at Goldman... Accenture (ACN) upgraded to Outperform from Market Perform at Cowen... Expedia (EXPE) upgraded to Outperform from Market Perform at JMP Securities... The Fresh Market (TFM) upgraded to Neutral from Underperform at Longbow... Marvell (MRVL) upgraded to Overweight from Equal Weight at Morgan Stanley... Health Care REIT (HCN) upgraded to Buy from Neutral at Mizuho... Gold Fields (GFI) upgraded to Buy from Hold at HSBC... eBay (EBAY) upgraded to Buy from Hold at Axiom... CNOOC (CEO) upgraded to Neutral from Underweight at JPMorgan... Quintiles (Q) upgraded to Buy from Neutral at SunTrust... DCT Industrial (DCT) upgraded to Neutral from Underperform at Credit Suisse... Pebblebrook Hotel (PEB) upgraded to Outperform from Neutral at Credit Suisse... Fortinet (FTNT) upgraded to Buy from Hold at Needham... BB&T (BBT) upgraded to Buy from Neutral at Guggenheim... Hercules Technology (HTGC) upgraded to Outperform from Neutral at Macquarie... InterXion (INXN) upgraded to Buy from Hold at Stifel.
07:13 EDTCEOCNOOC upgraded to Neutral from Underweight at JPMorgan
JPMorgan upgraded CNOOC to Neutral citing easing Nexen impairment risk and the potential for earnings to beat expectations.
May 20, 2015
09:36 EDTMCDActive equity options trading on open
Subscribe for More Information
07:12 EDTMCDMcDonald's annual meeting expected to be greeted with protests, Reuters says
Subscribe for More Information
05:56 EDTMCDStocks with implied volatility movement; MCD USO
Subscribe for More Information
May 19, 2015
09:50 EDTCEOCNOOC announces resignation of Chairman Wang Yilin
Subscribe for More Information
08:57 EDTCLDXLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
08:13 EDTMCDUnion group asks FTC to probe McDonald's, other big franchisers, WSJ reports
Subscribe for More Information
May 18, 2015
10:00 EDTHONHoneywell provides 2018 core organic growth targets
Subscribe for More Information
09:57 EDTHONHoneywell repeats FY15 EPS view $6.00-$6.15, consensus $6.09
Repeats FY15 revenue view $39B-$39.6B, consensus $39.39B. Sees FY15 segment margin up 170-200bps, sees FY15 free cash flow $4.2B-$4.3B. Sees 2H core organic sales acceleration. Says "confident" in 2015 outlook. Says busineses well positioned to grow.
09:55 EDTHONHoneywell sees Q2 EPS $1.56-$1.51, consensus $1.49
Subscribe for More Information
09:49 EDTHONEquity options with increasing volume
Subscribe for More Information
07:19 EDTHONElectric Products Group to hold a conference
EPG 2015 is being held in Longboat Key, Florida on May 18-20 with webcasted company presentations to begin on May 18 at 7:30 am; not all company presentations may be webcasted. Webcast Link
06:58 EDTHONHoneywell says M&A pipeline includes over 100 potential targets, Bloomberg says
Subscribe for More Information
May 15, 2015
16:01 EDTMCDOptions Update; May 15, 2015
iPath S&P 500 VIX Short-Term Futures down 20c to 20.06 Option volume leaders: AAPL BAC FB NFLX TWTR BABA CSCO TSLA MU GILD T MSFT AMZN MCD
12:15 EDTMCDMcDonald's call activity attributed to activist speculation
McDonald's May 97.5 and 98 calls are active eon total call volume of 56K (4K puts) on activist speculation. May call option implied volatility is at 18, May weekly is at 17, June is at 18, September is at 19; compared to 90-day average of 19 according to Track Data, suggesting large near term price movement.
11:09 EDTMCDRumor: McDonald's move higher attributed to activist speculation
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use